Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel H Solomon

Showing results (21-30 of 621) with videos related to

Pageof 63
Sort By:
Journal of the National Cancer Institute|June 29, 2007
Bisphosphonate therapy for cancer and prevalence of inflammatory jaw conditionsSook-Bin Woo, Daniel H Solomon
Nature Reviews. Rheumatology|January 1, 2020
Towards defining the safer use of opioids in rheumatologySeoyoung C Kim, Daniel H Solomon
Annals of the Rheumatic Diseases|February 14, 2016
Potential confounding in colchicine and cardiovascular disease studyDaniel H Solomon, Seoyoung C Kim
Arthritis & Rheumatology (Hoboken, N.J.)|October 22, 2014
Editorial: inflammation, disease-modifying antirheumatic drugs, lipids, and cardiovascular risk in rheumatoid arthritisKatherine P Liao, Daniel H Solomon
Nature Reviews. Rheumatology|July 26, 2020
Digital health technologies: opportunities and challenges in rheumatologyDaniel H Solomon, Robert S Rudin
Annals of the Rheumatic Diseases|March 2, 2016
Response to: 'Effects of colchicine on risk of cardiovascular events among patients with gout: as evidence accrues, is it time for a randomized trial?' by Giannopoulos and DeftereosDaniel H Solomon, Seoyoung C Kim
The Journal of Rheumatology|August 4, 2005
The cardiovascular system in rheumatic disease: the newest "extraarticular" manifestation?Daniel H Solomon, Nicola J Goodson
Nature Reviews. Rheumatology|February 10, 2010
Tumor necrosis factor blockade and the risk of viral infectionSeo Young Kim, Daniel H Solomon
Nature Clinical Practice. Rheumatology|June 30, 2007
A call for evidence-based quality measures: a goal worthy of pursuitDaniel H Solomon, Sherine E Gabriel
JAMA|September 13, 2007
Cardiovascular risk and the thiazolidinediones: déjà vu all over again?Daniel H Solomon, Wolfgang C Winkelmayer
Pageof 63

Showing results (21-30 of 621) with videos related to

Sort By:
Pageof 63
Journal of the National Cancer Institute|June 29, 2007
Bisphosphonate therapy for cancer and prevalence of inflammatory jaw conditionsSook-Bin Woo, Daniel H Solomon
Nature Reviews. Rheumatology|January 1, 2020
Towards defining the safer use of opioids in rheumatologySeoyoung C Kim, Daniel H Solomon
Annals of the Rheumatic Diseases|February 14, 2016
Potential confounding in colchicine and cardiovascular disease studyDaniel H Solomon, Seoyoung C Kim
Arthritis & Rheumatology (Hoboken, N.J.)|October 22, 2014
Editorial: inflammation, disease-modifying antirheumatic drugs, lipids, and cardiovascular risk in rheumatoid arthritisKatherine P Liao, Daniel H Solomon
Nature Reviews. Rheumatology|July 26, 2020
Digital health technologies: opportunities and challenges in rheumatologyDaniel H Solomon, Robert S Rudin
Annals of the Rheumatic Diseases|March 2, 2016
Response to: 'Effects of colchicine on risk of cardiovascular events among patients with gout: as evidence accrues, is it time for a randomized trial?' by Giannopoulos and DeftereosDaniel H Solomon, Seoyoung C Kim
The Journal of Rheumatology|August 4, 2005
The cardiovascular system in rheumatic disease: the newest "extraarticular" manifestation?Daniel H Solomon, Nicola J Goodson
Nature Reviews. Rheumatology|February 10, 2010
Tumor necrosis factor blockade and the risk of viral infectionSeo Young Kim, Daniel H Solomon
Nature Clinical Practice. Rheumatology|June 30, 2007
A call for evidence-based quality measures: a goal worthy of pursuitDaniel H Solomon, Sherine E Gabriel
JAMA|September 13, 2007
Cardiovascular risk and the thiazolidinediones: déjà vu all over again?Daniel H Solomon, Wolfgang C Winkelmayer
Pageof 63